title: [Ductal carcinoma in situ: role of the boost].
abstract: Ductal carcinoma in situ is defined as breast cancer confined to the ducts of the breast without evidence of penetration of the basement membrane. Local treatment quality represents one of the most prognostic factors as half of recurrences are invasive diseases. The main goal of adjuvant radiotherapy after conservative surgery is to decrease local recurrences and to permit breast conservation with low treatment-induced sequelae. Several randomized trials have established the impact of 50 Gy to the whole breast in terms of local control. Nevertheless, no randomized trial is still available concerning the role of the boost in this disease. In this review, we present updated results of the literature and we detail the French multicentric randomized trial evaluating the impact of a 16 Gy boost after 50 Gy delivered to the whole breast in 25 fractions and 33 days. This protocol will start inclusions in October 2008.
authors.affiliation: Département de radiothérapie, CRLC Val d'Aurelle - Paul-Lamarque, rue Croix-Verte, 34298 Montpellier cedex 5, France. david.azria@valdorel.fnclcc.fr
authors.forename: D
authors.initials: D
authors.lastname: Azria
authors.forename: H
authors.initials: H
authors.lastname: Auvray
authors.forename: I
authors.initials: I
authors.lastname: Barillot
authors.forename: P
authors.initials: P
authors.lastname: Baumann
authors.forename: A
authors.initials: A
authors.lastname: Benyoucef
authors.forename: F
authors.initials: F
authors.lastname: Bons-Rosset
authors.forename: P
authors.initials: P
authors.lastname: Bontemps
authors.forename: C
authors.initials: C
authors.lastname: Bourgier
authors.forename: C
authors.initials: C
authors.lastname: Breton-Callu
authors.forename: D
authors.initials: D
authors.lastname: Cowen
authors.forename: J
authors.initials: J
authors.lastname: Cretin
authors.forename: B
authors.initials: B
authors.lastname: Delalande
authors.forename: F
authors.initials: F
authors.lastname: Denis
authors.forename: S
authors.initials: S
authors.lastname: Ellis
authors.forename: Z
authors.initials: Z
authors.lastname: Gaci
authors.forename: J-M
authors.initials: JM
authors.lastname: Hannoun-Lévy
authors.forename: A
authors.initials: A
authors.lastname: Hasbini
authors.forename: C
authors.initials: C
authors.lastname: Hennequin
authors.forename: J-L
authors.initials: JL
authors.lastname: Lagrange
authors.forename: E
authors.initials: E
authors.lastname: Lartigau
authors.forename: I
authors.initials: I
authors.lastname: Latorzeff
authors.forename: M
authors.initials: M
authors.lastname: Le Blanc-Onfroy
authors.forename: I
authors.initials: I
authors.lastname: Lecouillard
authors.forename: C
authors.initials: C
authors.lastname: Lemanski
authors.forename: C
authors.initials: C
authors.lastname: Levy
authors.forename: P
authors.initials: P
authors.lastname: Maingon
authors.forename: C
authors.initials: C
authors.lastname: Marchal
authors.forename: A
authors.initials: A
authors.lastname: Monnier
authors.forename: O
authors.initials: O
authors.lastname: Pradier
authors.forename: S
authors.initials: S
authors.lastname: Racadot
authors.forename: P
authors.initials: P
authors.lastname: Romestaing
authors.forename: D
authors.initials: D
authors.lastname: Serin
authors.forename: J-M
authors.initials: JM
authors.lastname: Simon
authors.forename: E
authors.initials: E
authors.lastname: Teyssier
authors.forename: A
authors.initials: A
authors.lastname: Tallet
authors.forename: A
authors.initials: A
authors.lastname: Tolédano
authors.forename: Y
authors.initials: Y
authors.lastname: Belkacémi
mesh_terms: D001943:Breast Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D015337:Multicenter Studies as Topic; D009336:Necrosis; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011379:Prognosis; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic